XSHE
300318
Market cap630mUSD
Oct 09, Last price
5.30CNY
1D
2.51%
1Q
16.48%
Jan 2017
-41.50%
IPO
86.87%
Name
Beijing Bohui Innovation Biotechnology Group Co Ltd
Chart & performance
P/E
—
P/S
5.28
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
2.77%
Revenues
820m
-3.78%
Net income
-92m
L
CFO
-135m
L+249.35%
Dividend
Jul 12, 20180.005012 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Beijing Bohui Innovation Biotechnology Group Co., Ltd. is a Chinese enterprise that manages the full spectrum of diagnostic product operations, from initial research and development through manufacturing, sales, and post-sale support. Their offerings include a variety of diagnostic tools such as the GenPlex microfluidic automated system for nucleic acid detection, immunofluorescence detection solutions, and products for analyzing human trace elements. Additionally, the company provides advanced chemical analysis instrumentation, featuring atomic fluorescence spectrometers, photometers, mass spectrometers, chip ion sources, microfluidic flow chemical analysis systems, and ICP spectroscopy equipment, along with vital consumables for life sciences. Founded in 2001, the company is headquartered in Beijing, China. It adopted its current name, Beijing Bohui Innovation Biotechnology Group Co., Ltd., in August 2021, having previously been known as Beijing Bohui Innovation Biotechnology Co., Ltd.
Key people
Jia Liu
Chief Financial Officer · since 2023
Shuhui Niu
Deputy General Manager · since 2020
Wei Wang
Deputy General Manager, Director · since 2020
Lei Zhang
Deputy General Manager · since 2020
Chenglin Zeng
Chief Engineer · since 2025
Jupeng Diao
Director · since 2025
Haifeng Dong
Deputy General Manager, Secretary of the Board, Director · since 2023
Yan Jiang
Director · since 2023
Jiefang Li
Staff Elected Director · since 2025
Zhiwei Shen
Chairman of the Board, General Manager · since 2023
Jun Ban
Independent Director · since 2020
Jun Yin
Independent Director · since 2023
Xiaosu Zhang
Independent Director · since 2020
Li Zhao
Independent Director · since 2017
Headquarters & legal address
北京市昌平区生命园路9号院
昌平区, BJ 100000
CN
昌平区, BJ 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||